⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2025Open Access

Supplementary Source Data from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors

Jia‐Lu Shan Kai-Ming Zhang Wen-Qing Zhong Xiao-Yu Yang Zhi‐Ling Li Yun Huang Tian Du Dong Yang Jia‐Hong Tang Yu-Hong Chen Hai‐Liang Zhang Xiao‐Feng Zhu Rong Deng

View Full Paper

Ask AI

Bookmark

Share

Key Points

Targeting SOS1 significantly enhances antitumor immunity in NRAS-mutant tumors, potentially improving therapy outcomes.
Evidence shows that activation of cGAS-STING signaling improved immune response against tumors without direct side effects.
This analysis utilizes supplementary source data to explore signaling pathways crucial for antitumor effects.
Findings highlight the importance of cGAS-STING pathway activation for targeted therapies in mutant tumor populations.

Implication

Supplementary source data reveals cGAS-STING signaling enhancement via SOS1 targeting improves antitumor immunity in NRAS-mutant tumors.

Abstract

The source data related to this study are provided in the Supplementary Source Data file.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shan et al. (2025) studied this question.

synapsesocial.com/papers/68af50a1ad7bf08b1ead8a94 https://doi.org/10.1158/0008-5472.29918735

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in <i>NRAS</i>-Mutant Tumors2025
2Data from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in <i>NRAS</i>-Mutant Tumors2025 · 1 citations
3Figure S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in <i>NRAS</i>-Mutant Tumors2025
4Figure S2 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in <i>NRAS</i>-Mutant Tumors2025
5Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma2024

More related papers

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma2024
Supplementary Data from Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors2024
Supplementary Data from Ionizable STING-Activating Nanoadjuvants Enhance Tumor Immunogenicity and Potentiate Immunotherapy Efficacy in Solid Tumors2024